Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:424991C23C24.0C24.1
Who is this for?
Show terms as
4Active trials33Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Adenocarcinoma of the gallbladder and extrahepatic biliary tract is a type of cancer that starts in the cells lining the gallbladder or the bile ducts outside the liver. The gallbladder is a small organ under the liver that stores bile, a fluid that helps digest fats. The bile ducts are tubes that carry bile from the liver and gallbladder to the small intestine. When cancer develops in these areas, it is most often a type called adenocarcinoma, meaning it grows from gland-like cells. This cancer is sometimes called gallbladder cancer or bile duct cancer (cholangiocarcinoma), depending on exactly where it starts. It may also be referred to as biliary tract cancer. This cancer often grows silently in its early stages, which means many people do not notice symptoms until the disease has advanced. Common symptoms include yellowing of the skin and eyes (jaundice), pain in the upper right side of the belly, nausea, unexplained weight loss, and itchy skin. Because the gallbladder and bile ducts are located deep inside the body, tumors can grow quite large before causing noticeable problems. Treatment depends on how far the cancer has spread. Surgery to remove the tumor is the main option that can potentially cure the disease, but it is only possible in a minority of patients who are diagnosed early. For those with more advanced cancer, chemotherapy, radiation therapy, and targeted therapies may help slow the disease and manage symptoms. Research into new treatments, including immunotherapy and precision medicine, is ongoing and offering new hope for patients.

Also known as:

Key symptoms:

Yellowing of the skin and whites of the eyes (jaundice)Pain or discomfort in the upper right side of the abdomenNausea and vomitingUnexplained weight lossLoss of appetiteItchy skinDark-colored urinePale or greasy stoolsFeverBloating or a feeling of fullness in the bellyFatigue and low energyA lump or mass that can be felt in the upper abdomen

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Mar 2026TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort

Aarhus University Hospital

TrialNOT YET RECRUITING
Jan 2026A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

J-Pharma Co., Ltd. — PHASE3

TrialRECRUITING
Jul 2024Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals — PHASE3

TrialRECRUITING
Jan 2024Bile Omics for Diagnosing Indeterminate Biliary Strictures

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

TrialRECRUITING
Jul 2023The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases

RenJi Hospital

TrialNOT YET RECRUITING
Feb 2018Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California — PHASE1

TrialACTIVE NOT RECRUITING
Nov 2013

Nexavar: FDA approved

Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Adenocarcinoma of the gallbladder and extrahepatic biliary tract.

4 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

4 recruitingView all trials with filters →
Phase 32 trials
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 3
Actively Recruiting
· Sites: Duarte, California; Lone Tree, Colorado +182 more · Age: 1899 yrs
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Phase 3
Actively Recruiting
PI: Eric K Rowinsky, MD (Uniphar Development, LLC) · Sites: Gilbert, Arizona; Duarte, California +16 more · Age: 1899 yrs
Phase 11 trial
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Phase 1
Active
PI: Anthony El-Khoueiry, MD (University of Southern California) · Sites: Los Angeles, California; Newport Beach, California +1 more · Age: 1899 yrs
Other1 trial
Bile Omics for Diagnosing Indeterminate Biliary Strictures
Actively Recruiting
PI: Xueying Ding, MD (Shanghai General Hospital, Shanghai Jiao Tong Univ) · Sites: Shanghai, China · Age: 1890 yrs

Specialists

Showing 25 of 33View all specialists →
HK
Hedy Kindler
CHICAGO, IL
Specialist
PI on 7 active trials6 Adenocarcinoma of the gallbladder and extrahepatic biliary tract publications
AM
Anthony El-Khoueiry, MD
LOS ANGELES, CA
Specialist
PI on 2 active trials1 Adenocarcinoma of the gallbladder and extrahepatic biliary tract publication
SM
Syma Iqbal, MD
LOS ANGELES, CA
Specialist
PI on 3 active trials
SM
Scot C. Remick, MD
SCARBOROUGH, ME
Specialist
PI on 9 active trials
EM
Eric K Rowinsky, MD
BOCA RATON, FL
Specialist
PI on 1 active trial
SH
Stephen Michael Hahn
Specialist
PI on 1 active trial
RW
Robert P. Whitehead
Specialist
PI on 1 active trial
DK
Dieter Koeberle
Specialist
PI on 3 active trials
PP
Philip Philip
KISSIMMEE, FL
Specialist
PI on 2 active trials
SC
Steven Cohen
Specialist
PI on 1 active trial
YL
Ying-Bin Liu
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Nexavar

Bayer HealthCare Pharmaceuticals, Inc.

Nexavar — Contact Bayer HealthCare Pharmaceuticals, Inc.

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Adenocarcinoma of the gallbladder and extrahepatic biliary tract.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Adenocarcinoma of the gallbladder and extrahepatic biliary tractForum →

No community posts yet. Be the first to share your experience with Adenocarcinoma of the gallbladder and extrahepatic biliary tract.

Start the conversation →

Latest news about Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Disease timeline:

New recruiting trial: Bile Omics for Diagnosing Indeterminate Biliary Strictures

A new clinical trial is recruiting patients for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

New recruiting trial: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

A new clinical trial is recruiting patients for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

New recruiting trial: A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

A new clinical trial is recruiting patients for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and what does that mean for my treatment options?,Has my tumor been tested for genetic mutations, and am I eligible for any targeted therapies or immunotherapy?,Is surgery an option for me, and if so, what would it involve?,What are the goals of my treatment — is it aimed at curing the cancer or managing it?,Are there any clinical trials I should consider?,What symptoms should prompt me to call you or go to the emergency room?,Should I see a genetic counselor to understand if my family members are at increased risk?

Common questions about Adenocarcinoma of the gallbladder and extrahepatic biliary tract

What is Adenocarcinoma of the gallbladder and extrahepatic biliary tract?

Adenocarcinoma of the gallbladder and extrahepatic biliary tract is a type of cancer that starts in the cells lining the gallbladder or the bile ducts outside the liver. The gallbladder is a small organ under the liver that stores bile, a fluid that helps digest fats. The bile ducts are tubes that carry bile from the liver and gallbladder to the small intestine. When cancer develops in these areas, it is most often a type called adenocarcinoma, meaning it grows from gland-like cells. This cancer is sometimes called gallbladder cancer or bile duct cancer (cholangiocarcinoma), depending on exact

How is Adenocarcinoma of the gallbladder and extrahepatic biliary tract inherited?

Adenocarcinoma of the gallbladder and extrahepatic biliary tract follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Adenocarcinoma of the gallbladder and extrahepatic biliary tract typically begin?

Typical onset of Adenocarcinoma of the gallbladder and extrahepatic biliary tract is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract?

Yes — 4 recruiting clinical trials are currently listed for Adenocarcinoma of the gallbladder and extrahepatic biliary tract on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Adenocarcinoma of the gallbladder and extrahepatic biliary tract?

25 specialists and care centers treating Adenocarcinoma of the gallbladder and extrahepatic biliary tract are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Adenocarcinoma of the gallbladder and extrahepatic biliary tract?

1 patient support program are currently tracked on UniteRare for Adenocarcinoma of the gallbladder and extrahepatic biliary tract. See the treatments and support programs sections for copay assistance, eligibility, and contact details.